EQUASENS : ACQUISITION DES ACTIVITES DIS ET RESURGENCES Villers-lès-Nancy, le 30 juin 2025 - 18h00 (CET) COMMUNIQUE DE PRESSE EQUASENS ANNONCE L’ACQUISITION DES ACTIVITES DIS ET RESURGENCES ET RENFORCE AINSI SA POSITION SUR LE MARCHE DES LOGICIELS POUR LES ETABLISSEMENTS DE SANTE. Renforcement d'un acteur de référence dans les logiciels hospitaliers et médico-sociaux Opération finalisée : acquisition de la société Novaprove, éditeur du logiciel ResUrgences et du fonds de commerce de l'activité DIS (gamme GESDIS, FACDIS, ARCADIS)Périmètre consolidé : plus de 300 clients dans le secteur...
Equasens: acquisition of DIS and RESURGENCES BUSINESSES Villers-lès-Nancy (France), 30 June 2025 - 06:00 PM (CET) PRESS RELEASE EQUASENS ACQUIRES DIS AND RESURGENCES BUSINESSES, STRENGTHENING ITS POSITION IN THE MARKET OF SOFTWARE SOLUTIONS FOR HEALTHCARE ESTABLISHMENTS. Strengthening the position of a leading provider of software solutions for hospitals and the medical-social sector Transaction finalised: acquisition of Novaprove, publisher of ResUrgences software and the DIS business assets, (GESDIS, FACDIS, ARCADIS ranges)Acquisition scope: more than 300 customers in th...
Feedback of the companies present at the ODDO BHF Nextcap Forum Company Country Market cap. (m) Company Country Market cap. (m) Accsys Technologies € 124 Hoffmann Green € 62 Afyren € 72 Hornbach € 1 451 Altri € 1 058 IDI € 537 AMG € 550 Implenia CHF 973 AmRest PLN 3 544 Jacquet Metals € 494 Arcure € 29 Kloeckner & Co € 653 Arverne 194 Knaustabbert € 144 Austriacard Holdings € 188 Lna Santé € 270 Bastide € 218 Medincell € 398 Befesa € 1 116 Nacon € 63 CAF € 1 649 N...
Our 14th edition of the ODDO BHF Nextcap Forum took place on 11 June in Paris, and on 12 June virtually. 96 companies and 170 investors were present for more than 700 meetings organized. Overall, we noted a still cautious tone from companies, with limited visibility on a solid rebound in a persistently uncertain market environment (geopolitical situation, US politics, etc.), even if there are some signs of recovery and certain sectors remain very well positioned (leisure, energy, defence). At th...
Equasens: availability of AGM preparatory materials Villers-lès-Nancy, 6 June 2025 - 6:00 p.m. (CET) PRESS RELEASE ANNUAL ORDINARY GENERAL MEETING MEETING NOTICE ON-LINE AVAILABILITY OF MEETING MATERIALS WEBCAST LIVE EQUASENS hereby provides notice to shareholders of the Annual Ordinary General Meeting to be held on Wednesday, June 25, 2025 at 5.30 pm at the Company’s registered office located in Villers-lès-Nancy (Technopôle de Nancy-Brabois - 5 Allée de Saint Cloud). The original French language version of the agenda and the resolutions submitted by the Board of Directors to the Or...
EQUASENS : modalités de mise à disposition des documents préparatoires à l'AG Villers-lès-Nancy, le 6 juin 2025 – 18:00 (CET) COMMUNIQUE DE PRESSE ASSEMBLEE GENERALE ORDINAIRE ANNUELLE AVIS DE CONVOCATION MISE EN LIGNE DES DOCUMENTS PREPARATOIRES RETRANSMISSION EN DIRECT La société EQUASENS invite ses actionnaires à participer à l’Assemblée Générale Ordinaire Annuelle qui se réunira le mercredi 25 juin 2025, à 17 heures 30, au Siège Social à Villers-lès-Nancy (Technopôle de Nancy-Brabois - 5 Allée de Saint Cloud). L'avis de réunion préalable, comprenant notamment l'ordre du jour de...
Equasens: Q1 revenue at 31 March 2025 Villers-lès-Nancy, 12 May 2025 - 6:00 PM (CET) PRESS RELEASE Q1 revenue at 31 March 2025: €57.0m+ 6.9% growth on a reported basis and + 5.9% like-for-like Q1 2025 REVENUE (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthLike-for-like change(organic growth)Equasens Group 53.357.03.76.9%0.53.25.9%Q1 2025 revenue / Division (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthLike-for-like change(organic growth)Pharmagest39.842.02.25.5% 2.25.5%Axigate Link7.88.30.45.5% 0.45.5%e-Connec...
EQUASENS : Chiffre d’affaires au 31 mars 2025 Villers-lès-Nancy, le 12 mai 2025 - 18h00 (CET) COMMUNIQUE DE PRESSE Chiffre d’affaires au 31 mars 2025 à 57,0 M€+ 6,9% en croissance publiée et + 5,9% en croissance organique CA T1 2025 (M€)Publié 2024Publié 2025Variation/publiéDont Croissances externesVariation/périmètre comparable (croissance organique)Groupe Equasens 53,357,03,76,9%0,53,25,9%CA T1 2025 / Division (M€)Publié 2024Publié 2025Variation/publiéDont Croissances externesVariation/périmètre comparable (croissance organique)Pharmagest39,842,02,25,5% 2,25,5%Axigate Link7,88,30,45,5%...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.